Promakhos Therapeutics
Bacterial molecules platform for innate healing and inflammation control.
About
Promakhos Therapeutics is a Boston-based biotechnology company pioneering a new class of immunotherapies that restore the body’s ability to resolve chronic inflammation. Rather than suppressing the immune system, their approach reactivates innate immune pathways using small molecules inspired by the body’s own microbiota. Their lead program targets Crohn’s disease, with preclinical data showing oral bioavailability and efficacy in mouse models.
Founded in 2021 by Katerina Chatzi and Jasper Edgar Neggers, Promakhos is also backed by Y Combinator and has raised over $2.5M to date. The company operates out of the Pagliuca Harvard Life Lab and is advancing toward clinical development.
Want to join our portfolio?
If you have an idea you are excited about that fits our ethos, start an application. One of our team members will get back to you within a month.